Stay updated on Safety Efficacy Selinexor Pembrolizumab Combo in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Safety Efficacy Selinexor Pembrolizumab Combo in Melanoma Clinical Trial page.

Latest updates to the Safety Efficacy Selinexor Pembrolizumab Combo in Melanoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.3%
- Check20 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference6%
- Check28 days agoNo Change Detected
- Check49 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.3%
- Check64 days agoChange DetectedThe web page has updated its version from v2.14.4 to v2.15.0, indicating a revision in the content. The phrase 'Here’s how you know' has been modified, suggesting a change in the presentation or explanation of information.SummaryDifference1.0%
- Check71 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.3%
- Check107 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
Stay in the know with updates to Safety Efficacy Selinexor Pembrolizumab Combo in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety Efficacy Selinexor Pembrolizumab Combo in Melanoma Clinical Trial page.